Publications by authors named "Julie L Richardson"
From 8 December 2021 to 26 January 2023, tixagevimab-cilgavimab (T-C) was authorized for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary team to communicate, screen, approach, and administer T-C to eligible patients. Twenty-seven patients were eligible.
View Article and Find Full Text PDFArticle Synopsis
- * Conducted on healthy volunteers, the study found that SJ733 was well-tolerated with no serious side effects, and the boosted regimen significantly increased drug exposure compared to unboosted doses.
- * The findings promote the continued development of SJ733 and introduce a new strategy to improve antimalarial treatment by enhancing drug pharmacokinetics through a boosting agent.
Background: (+)-SJ000557733 (SJ733) is a novel, orally bioavailable inhibitor of Plasmodium falciparum ATP4. In this first-in-human and induced blood-stage malaria phase 1a/b trial, we investigated the safety, tolerability, pharmacokinetics, and antimalarial activity of SJ733 in humans.
Methods: The phase 1a was a single-centre, dose-escalation, first-in-human study of SJ733 allowing modifications to dose increments and dose-cohort size on the basis of safety and pharmacokinetic results.